VRTX Vertex Pharmaceuticals
- 445.210
- +4.570+1.04%
- 445.170
- -0.040-0.01%
Vertex Pharmaceuticals News
Vertex Pharmaceuticals's Options Frenzy: What You Need to Know
Whales with a lot of money to spend have taken a noticeably bearish stance on Vertex Pharmaceuticals.
Jennifer Schneider Elected to Vertex Board of Directors
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Jennifer Schneider, M.D., M.S., has been elected to its Board of Directors as an independent director. Dr. Schneider has more than two decades of
Pfizer, Freeport-McMoRan, Vertex Pharmaceuticals And A Major Tech Stock On CNBC's 'Final Trades'
On CNBC's "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management said under $30, Pfizer Inc. (NYSE:PFE) is a gift.Pfizer is looking to build on the success of its COVID-19 vaccine
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 10 Years
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 10 years by 9.86% on an annualized basis producing an average annual return of 20.63%.
Wolfe Research Adjusts Price Target on Vertex Pharmaceuticals to $520 From $497
Vertex Pharmaceuticals (VRTX) has an average outperform rating and a price target range of $325 to $577, according to analysts polled by Capital IQ. Price: 430.50, Change: +0.57, Percent Change: +0.13
Vertex Pharmaceuticals Is Racing Towards a New Blockbuster: Why the Stock Is a Smart Buy
8 Out of 12 S&P 500 Healthcare Companies Beat Profit Consensus This Week: Earnings Scorecard
Alpine Immune Sciences, Vertex Pharmaceuticals Deal Crosses Another Milestone
Alpine Immune Sciences (ALPN) and Vertex Pharmaceuticals (VRTX) said Friday the waiting period under the Hart-Scott-Rodino antitrust act related to their merger deal expired Thursday. Vertex has agree
HHS Panel to Vote in Nov. on DMD Screening for Newborns
Press Release: Alpine Immune Sciences Reports First Quarter 2024 Financial Results
Alpine Immune Sciences Reports First Quarter 2024 Financial Results SEATTLE--(BUSINESS WIRE)--May 09, 2024-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy compa
Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) CEO Will Probably Have Their Compensation Approved By Shareholders
We have been pretty impressed with the performance at Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) recently and CEO Reshma Kewalramani deserves a mention for their role in it.
Decoding Vertex Pharmaceuticals Inc (VRTX): A Strategic SWOT Insight
Vertex Pharmaceuticals Inc (NASDAQ:VRTX), a leading global biotechnology firm, recently released its 10-Q filing on May 7, 2024, offering a detailed glimpse into its financial and operational performance.
Stifel Nicolaus Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX)
In a report released yesterday, Paul Matteis from Stifel Nicolaus maintained a Hold rating on Vertex Pharmaceuticals (VRTX), with a price target of $420.00.
A Closer Look at Vertex Pharmaceuticals's Options Market Dynamics
Financial giants have made a conspicuous bullish move on Vertex Pharmaceuticals.
Balancing Act: Vertex Pharmaceuticals' Growth Prospects and Valuation Concerns Justify a Hold Rating
Vertex Pharmaceuticals Incorporated Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) investors will be delighted, with the company turning in some strong numbers with its latest results. Vertex Pharmaceuticals beat earnings, with
Vertex Pharmaceuticals First Quarter 2024 Earnings: Beats Expectations
Vertex Pharmaceuticals Sell Rating Maintained Amid Unsustainable Performance and Uncertain Pipeline Progress
5 Reasons Vertex Pharmaceuticals Is a Screaming Buy on the Dip
Sell Rating on Vertex Pharmaceuticals Amid Non-Recurring Gains and Overstated Sales
Analysis
Price Target
No Data
